The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1737
ISSUE 1737
September 15, 2025
Issue 1737
- Acoltremon (Tryptyr) for Dry Eye Disease
- A New Heart Failure Indication for Finerenone (Kerendia)
- Inclisiran (Leqvio) Monotherapy for LDL-Cholesterol Reduction
- Ceftobiprole Medocaril (Zevtera) — A New Cephalosporin Antibiotic
- In Brief: Embryotoxicity REMS Removal for Endothelin Receptor Antagonists
- Sunvozertinib (Zegfrovy) for NSCLC (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Acoltremon (Tryptyr) for Dry Eye Disease
September 15, 2025 (Issue: 1737)
The FDA has approved acoltremon 0.003% ophthalmic
solution (Tryptyr – Alcon) for treatment of dry eye
disease. Acoltremon is the first transient receptor
potential melastatin 8 (TRPM8) thermoreceptor
agonist to be approved in the US for this...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.